Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
4
Neutral
5
Bullish
5
Bearish
4
Neutral
5
Bullish
37
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stock
Alkem Laboratories Limited is a Mumbai-headquartered integrated pharmaceutical company that develops, manufactures and sells branded generics, generic formulations, APIs, biosimilars and nutraceuticals in India and internationally, supported by 18 manufacturing facilities, R&D centres and a growing subsidiary ecosystem (Enzene, Alkem MedTech, Ascend, Pharmacor and others).
Q3 FY26 results showed resilient performance: consolidated revenue of ₹37,368 million (+10.7% YoY), EBITDA ₹8,280 million at a 22.2% margin and PAT of ₹6,360 million, while international businesses grew 26.6% YoY led by the US and non‑US markets, signalling successful portfolio and geographic execution.
Strategic expansion into MedTech was announced via a binding term sheet to acquire majority stake in Occlutech, giving Alkem immediate presence in minimally invasive cardiac implants and a high‑value device pipeline, with management projecting Alkem MedTech to become a meaningful growth and margin contributor over the next 3–5 years.
R&D and pipeline depth are notable: Alkem disclosed 188 ANDA filings and 167 approvals (including tentative), ongoing NDAs/BLAs, Q3 R&D spend of ₹1,390 million (3.7% of sales) and planned GLP‑1 semaglutide domestic launch in March 2026, highlighting biologics and specialty chronic therapies as focus areas.
Balance sheet strength and regulatory progress underpin optionality: net cash of ₹55.9 billion as of Dec 31, 2025, multiple facilities with recent EIRs or clean inspection outcomes, and an active ANDA approval cadence that supports US growth and cross‑border expansion.
Pharmaceuticals & Biotechnology
Pharmaceuticals
66,606 Cr
Low Risk
28.9
36.2
2.2
4.8
5,933.00
4,716.75
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1543.70 | 83,293 Cr | 93.72 | 15.72 | 0.13 | 16.77 | 16.14 | 8.47 | ||
426.25 | 69,466 Cr | 180.15 | 2.02 | 0.12 | 1.14 | 3.64 | 0.58 | ||
5571.50 | 66,606 Cr | 28.94 | 4.82 | 0.95 | 16.66 | 18.61 | 11.27 | ||
2209.85 | 62,362 Cr | 45.79 | 5.93 | 0.11 | 28.08 | 32.70 | 6.84 | ||
25850.45 | 54,932 Cr | 35.39 | 11.51 | 1.84 | 32.51 | 42.54 | 23.87 | ||
1775.00 | 45,182 Cr | 39.59 | 5.60 | 0.34 | 14.15 | 18.58 | 9.63 | ||
3338.75 | 41,550 Cr | 39.35 | 9.18 | 0.84 | 23.33 | 29.09 | 17.16 | ||
| Median: 7 Co. | — | 2209.85 | 62,362 Cr | 39.59 | 5.93 | 0.34 | 16.77 | 18.61 | 9.63 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Alkem Laboratories Ltd (ALKEM) is currently trading at 5,571.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Alkem Laboratories Limited is a Mumbai-headquartered integrated pharmaceutical company that develops, manufactures and sells branded generics, generic formulations, APIs, biosimilars and nutraceuticals in India and internationally, supported by 18 manufacturing facilities, R&D centres and a growing subsidiary ecosystem (Enzene, Alkem MedTech, Ascend, Pharmacor and others). Q3 FY26 results showed resilient performance: consolidated revenue of ₹37,368 million (+10.7% YoY), EBITDA ₹8,280 million at a 22.2% margin and PAT of ₹6,360 million, while international businesses grew 26.6% YoY led by the US and non‑US markets, signalling successful portfolio and geographic execution. Strategic expansion into MedTech was announced via a binding term sheet to acquire majority stake in Occlutech, giving Alkem immediate presence in minimally invasive cardiac implants and a high‑value device pipeline, with management projecting Alkem MedTech to become a meaningful growth and margin contributor over the next 3–5 years. R&D and pipeline depth are notable: Alkem disclosed 188 ANDA filings and 167 approvals (including tentative), ongoing NDAs/BLAs, Q3 R&D spend of ₹1,390 million (3.7% of sales) and planned GLP‑1 semaglutide domestic launch in March 2026, highlighting biologics and specialty chronic therapies as focus areas. Balance sheet strength and regulatory progress underpin optionality: net cash of ₹55.9 billion as of Dec 31, 2025, multiple facilities with recent EIRs or clean inspection outcomes, and an active ANDA approval cadence that supports US growth and cross‑border expansion.
Over the past 52 weeks, Alkem Laboratories Ltd has traded between a low of ₹4,716.75 and a high of ₹5,933.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Alkem Laboratories Ltd has a market capitalization of approximately 66,606.07. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Alkem Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 28.94 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 66,606.07 Cr, Alkem Laboratories Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Alkem Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Alkem Laboratories Ltd is 28.94. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The text says the stock rose after Alkem Laboratories reported a healthy set of earnings for the March quarter, with the share price jumping over 6% intraday.
The material describes BEC as attackers compromising email accounts and using domain spoofing to impersonate executives, leading a treasury manager to transfer funds to a fraudulent account.
Promoter-linked entities sold about 1.49% (around 1.5%) stake via NSE block deals worth about Rs 930 crore at Rs 5,200 per share, drawing investor attention.
Alkem launched semaglutide in ready-to-use, single-shot pre-filled syringes in India, in addition to earlier disposable and reusable pen formats.
AGM/EGM Notice
Alkem Laboratories Ltd: Notice of 52nd AGM to be held via VC/OAVM on Thursday, 27 August, 2026 at 11:00 a.m. IST; Board recommended final dividend of Rs.10/- per equity share (Rs.2/- face) for FY 2025-26, subject to member approval; dividend payable from 1 September, 2026 if approved.
Merger/Acquisition
Alkem Laboratories informs that its wholly-owned subsidiary Alkem Medtech executed a First Supplementary Agreement on 26 th June, 2026 to acquire at least 51% and up to 55% of Occlutech Holding AG, pursuant to the SPA dated 6 th March, 2026.
